Literature DB >> 32663296

Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste.

Bart L Scott1.   

Abstract

This article has a companion Counterpoint by Soiffer.
© 2020 by The American Society of Hematology.

Entities:  

Mesh：

Year:  2020        PMID： 32663296      PMCID： PMC7362353          DOI： 10.1182/bloodadvances.2019000388

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  24 in total

1.  Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.

Authors:  Martin S Tallman; Gordon W Dewald; Sharavi Gandham; Brent R Logan; Armand Keating; Hillard M Lazarus; Mark R Litzow; Jayesh Mehta; Tanya Pedersen; Waleska S Pérez; Jacob M Rowe; Meir Wetzler; Daniel J Weisdorf
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

2.  Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Charles Craddock; Myriam Labopin; Marie Robin; Juergen Finke; Patrice Chevallier; Ibrahim Yakoub-Agha; Jean Henri Bourhis; Henrik Sengelov; Didier Blaise; Thomas Luft; Michael Hallek; Nicolaus Kröger; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

3.  Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Authors:  Eolia Brissot; Myriam Labopin; Marielle M Beckers; Gérard Socié; Alessandro Rambaldi; Liisa Volin; Jürgen Finke; Stig Lenhoff; Nicolaus Kröger; Gert J Ossenkoppele; Charles F Craddock; Ibrahim Yakoub-Agha; Günhan Gürman; Nigel H Russell; Mahmoud Aljurf; Michael N Potter; Armon Nagler; Oliver Ottmann; Jan J Cornelissen; Jordi Esteve; Mohamad Mohty
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

4.  Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Thierry Guillaume; Florent Malard; Leonardo Magro; Myriam Labopin; Reza Tabrizi; Cécile Borel; Patrice Chevallier; Stéphane Vigouroux; Pierre Peterlin; Alice Garnier; Marie-Thérèse Rubio; Anne Huynh; Noël Milpied; Philippe Moreau; Béatrice Gaugler; Ibrahim Yakoub-Agha; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2019-05-14       Impact factor: 5.483

5.  Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML.

Authors:  Bart Scott; H Joachim Deeg; Barry Storer; Thomas Chauncey; Stephen Petersdorf; John Slattery; Frederick Appelbaum
Journal:  Leuk Lymphoma       Date:  2004-12

6.  Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.

Authors:  H Pfeifer; B Wassmann; W Bethge; J Dengler; M Bornhäuser; M Stadler; D Beelen; V Vucinic; T Burmeister; M Stelljes; C Faul; P Dreger; A Kiani; K Schäfer-Eckart; R Schwerdtfeger; E Lange; B Kubuschok; H A Horst; M Gramatzki; P Brück; H Serve; D Hoelzer; N Gökbuget; O G Ottmann
Journal:  Leukemia       Date:  2012-12-05       Impact factor: 11.528

7.  Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome.

Authors:  Moreno Festuccia; H Joachim Deeg; Theodore A Gooley; Kelsey Baker; Brent L Wood; Min Fang; Brenda M Sandmaier; Bart L Scott
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-06       Impact factor: 5.742

8.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.

Authors:  Roland B Walter; Sarah A Buckley; John M Pagel; Brent L Wood; Barry E Storer; Brenda M Sandmaier; Min Fang; Boglarka Gyurkocza; Colleen Delaney; Jerald P Radich; Elihu H Estey; Frederick R Appelbaum
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113

9.  Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.

Authors:  V Bachanova; D I Marks; M-J Zhang; H Wang; M de Lima; M D Aljurf; M Arellano; A S Artz; U Bacher; J-Y Cahn; Y-B Chen; E A Copelan; W R Drobyski; R P Gale; J P Greer; V Gupta; G A Hale; P Kebriaei; H M Lazarus; I D Lewis; V A Lewis; J L Liesveld; M R Litzow; A W Loren; A M Miller; M Norkin; B Oran; J Pidala; J M Rowe; B N Savani; W Saber; R Vij; E K Waller; P H Wiernik; D J Weisdorf
Journal:  Leukemia       Date:  2013-08-30       Impact factor: 11.528

10.  CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Authors:  Marcos de Lima; Betul Oran; Richard E Champlin; Esperanza B Papadopoulos; Sergio A Giralt; Bart L Scott; Basem M William; Joel Hetzer; Eric Laille; Becky Hubbell; Barry S Skikne; Charles Craddock
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-20       Impact factor: 5.742
View more
  2 in total

Review 1.  60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Authors:  Nicoletta Cieri; Katie Maurer; Catherine J Wu
Journal:  Cancer Res       Date:  2021-06-09       Impact factor: 12.701

2.  Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation.

Authors:  Siok-Keen Tey; Steven W Lane
Journal:  Blood Adv       Date:  2022-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.